# Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

> **NCT05007782** · PHASE1 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 416 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Denikitug
- **DRUG:** Zimberelimab

## Key facts

- **NCT ID:** NCT05007782
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-18
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 416 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05007782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05007782, "Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05007782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*